Neurocrine Biosciences | NBIX - Creditori Commerciali





Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
ALKERMES USD 107.95M 39.95M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Biogen USD 432M 18.9M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Cytokinetics USD 105.62M 83.53M 2025-12
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Exelixis USD 29.62M 4.27M 2025-12
Gilead Sciences USD 808M 226M 2025-09
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Incyte USD 1.63B 1.46B 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Pfizer USD 5.02B 142M 2025-09
Prothena USD 5.88M 4.63M 2025-12
Regeneron Pharmaceuticals USD 5.83B 4.93B 2025-12
Repligen USD 30.01M 584K 2025-12
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Teva Pharmaceutical Industries USD 2.53B 176M 2025-12
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12
Xoma USD 2.65M 1.52M 2025-09